Modelling the cost-effectiveness of HIV care shows a clear benefit when transmission risk is considered in the calculations – A message for Central and Eastern Europe

Justyna D. Kowalska1,2*, Grzegorz Wójcik3, Jakub Rutkowski3, Magdalena Ankiersztejn-Bartczak4, Ewa Siewaszewicz5

1 Department of Adults’ Infectious Diseases, Medical University of Warsaw, Warsaw, Poland, 2 HIV Out-Patients Clinic, Hospital for Infectious Diseases in Warsaw, Warsaw, Poland, 3 HTA Consulting, Cracow, Poland, 4 Foundation of Social Education (FES), Warsaw, Poland, 5 Gilead Sciences, Warsaw, Poland

* jdkowalska@gmail.com

Abstract

Background

HIV epidemic remains a major global health issue. Data from cost-effectiveness analyses base on CD4+ count and morbidity in patients with symptomatic and asymptomatic HIV infection. The approach adopted in these analyses includes many other factors, previously not investigated. Additionally, we evaluate the impact of sexual HIV transmission due to delayed cART on the cost-effectiveness of care.

Methods

A lifetime Markov model (1-month cycle) was developed to estimate the cost per quality adjusted life years (QALY) for a 1- and 3-year delay in starting cART (as compared to starting immediately at linkage to care) lifetime costs, clinical outcomes and cost-effectiveness. Patients were categorized into having asymptomatic HIV, AIDS, Hodgkin’s Lymphoma, and non-AIDS defining condition. Mortality rates and utility values were obtained from published literature. The number of new infected persons was estimated on the basis of sexual orientation, the number of sexual partners per year, the number of sex acts per month, frequency of condom use and use of cART. For the input Test and Keep in Care (TAK) project cohort data were used. Costs of care, cART and potential life-years lost were based on estimated total costs and the difference in expected QALY gained between an HIV-positive and an average person in Polish population. Costs were based on real expenditures of the Ministry of Health, National Health Fund, available studies and experts’ opinion. Costs and effects were discounted at rates of 5% and 3.5%, respectively.

Results

Input data were available for 141 patients form TAK cohort. The estimated number of new HIV infections in low, medium and high risk transmission groups were 0.28, 0.61, 2.07 with 1
and 0.82, 1.80, 6.11 with a 3-year delay, respectively. This reflected QALY loss due to cART delay of 0.52, 1.13, 3.84 and 2.02, 4.43, 15.03 for a 1- and 3-year delay, respectively. If additional costs of treatment and potential life-years lost due to new HIV infections were not taken into account, initiating cART immediately at linkage to care was not cost-saving irrespective of cART delay. Otherwise, when additional costs and QALY lost due to new HIV infections were included, immediate cART initiation was cost-saving regardless of the chosen scenarios.

Conclusions
If new HIV infections are not taken into account, then starting cART immediately does not dominate comparing to delaying cART. When taking into account HIV transmission in cost-effectiveness analysis, immediate initiation of HIV treatment is a profitable decision from the public payer’s perspective.

Introduction
HIV epidemic remains one of the most challenging areas in both global and national health management. The accomplishments of the recent 15 years have brought less toxic and highly effective antiretroviral therapy, leading to a significant decrease in both morbidity and mortality of HIV positive persons [1, 2]. However lives improved and lives saved do not always translate into economic savings, due to high costs of treatment and care, the life-long character of such care and continuously increasing number of people to treat [3].

In comparison with the number of already diagnosed persons, the number of new infections is substantial and remains quite stable every year. According to the most recent UNAIDS report published in 2016, the number of people living with HIV increased globally from 33.3 million in 2010 to 36.7 million in 2015 with the number of people on combination antiretroviral therapy (cART) increasing from 7.5 million to over 17 million [4]. The gains in treatment are to be responsible for a 26% decrease in deaths, which in turn translates into more people requiring treatment and care, namely more costs.

At the same time recent years have brought strong evidence for the role of cART in protecting HIV transmission through sexual acts when an HIV positive person is on effective treatment [5, 6]. It is, therefore, of great interest for both health care providers and public payers to understand the economic impact of investing in early cART on the savings made through prevention of HIV transmission [7].

For national strategies which would prioritise early cART among other life-saving therapies, governments and stakeholders require tools that are developed on the basis of national or regional epidemiology, the costs and health structure. Cost-effectiveness analyses have recently become widely accepted as the standard approach to health. In our model we applied, as advised by the World Health Organization, the convention to report the intervention as “cost-saving” (both cheaper and better) with the absolute magnitude of savings and health gains [8].

Finally we have used real life data from the existing cohort of HIV positive persons followed in the Test and Keep in Care (TAK) project. The TAK project collects information on patients diagnosed with HIV between 2010 and 2013 in voluntary counselling and testing centres (VCTs) in central Poland, follows their linkage to HIV clinics and further routine clinical care. A unique characteristic of this cohort is the availability of information provided by VCTs.
clients in a standard anonymous questionnaire before performing an HIV test, including detailed information about sexual behaviors and preferences [9, 10].

**Methods**

A lifetime Markov model was built to estimate quality adjusted life years (QALY) and costs of treatment of an HIV infected patient, from the public payer’s perspective (Fig 1). The model was developed in Microsoft Excel 2013 with Visual Basic Applications. The model allowed to perform cost-utility analysis, to estimate the ratio of incremental cost per additional year of life in full health (ICER) and to perform probabilistic sensitivity analysis, in order to allow the estimation of confidence intervals for deterministic results and scatter of results. In addition, a cost-effectiveness acceptability curve (CEAC) was generated to test for the effectiveness threshold.

Our analyses were performed to compare two hypothetical, independent cohorts of patients, one linked to immediate care and cART treatment (Immediate Initiation Group, IIG), while the second cohort started cART treatment after an arbitrarily chosen time delay (Deferred Initiation Group, DIG). Modelling the distribution of patients in these two cohorts took place in two independent steps. First, based on the baseline characteristics of patients followed in TAK cohort: mean CD4+ cells count, median HIV RNA and others (Table 1), an average level of CD4+ cells count was estimated for both cohorts in each cycle of the predetermined time horizon (S1 File). Next, using predetermined input parameters and specified CD4+ cell count, the main Markov model simulation was performed.

The model has one-month cycles and takes into account 33 events or illnesses divided into 18 health states and 8 additional events or diseases affecting estimated costs and the length of life (Table 2). The baseline state of the model is an asymptomatic HIV, that was the people with HIV who did not experience additional comorbidities. In each cycle of analysis, patients were distributed between health states with assigned corresponding probabilities. We made the assumption, that after changing baseline health state it was not possible for the person to change their health state, except for death incidence, there was no possibility of the occurrence of the same event repeatedly and no possibility of having several diseases at the same time (Fig 1). In other words, health states representing AIDS-defining illnesses, non-AIDS defining illnesses, and Hodgkin’s Lymphoma were transient states between an asymptomatic HIV and

![Fig 1. Markov model for HIV treatment. *They do not determine independent health states. Only additionally costs and deaths due to cardiovascular events and other illnesses were charged, regardless of the state of health in each cycle of analysis.](https://doi.org/10.1371/journal.pone.0186131.g001)
death. Due to insufficient data on conditional transitions, a simplified assumption was adopted. This approach in case of the cohort of patients allows to obtain results corresponding to reality.

In addition, based on presumed sexual behaviour of a person, the proportion of new HIV-infected people through sexual contact was estimated. New infections were calculated for a set period of time equal to the treatment delay in the base case scenario. Moreover, the costs and life years lost for newly infected persons were calculated (detailed description in “Transmission Model” part).

CD4+ model

The prediction of mean level of CD4+ cell count was independent for each modelled cohort. In both IIG and DIG cohort we assumed the average level of CD4+ lymphocytes caused by treatment according to the data published by Mocroft et al. in 2007[11]. Additionally, we have assumed that once a patient achieved full treatment response (serum HIV RNA <50 copies/ml), it was maintained throughout the analysed period of time. However, a decline in the mean CD4+ cell count until the initiation of cART treatment was programmed for DIG cohort based on the linear model presented by the Natural History Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord [12].

Disease progression probabilities

Specific transition probabilities depend on the current age or previously estimated mean lymphocyte CD4+ count in each model cycle. In case of AIDS-defining illnesses, we used data about the frequency of various diseases related to different levels of CD4+ cells count, retrieved from Mocroft 2013 [13]. Incidence rates of AIDS-defining illnesses per 1000 patients were converted into monthly probabilities of the occurrence of illness. For other non-AIDS related diseases and events, probabilities were linked in each model cycle with the actual age, grouped into 3 categories: <50, 50–64 and at least 65 years, respectively, based on published data [14–18]. In addition, we assumed that regardless of being in one of defined health states, the analyzed patient can independently experience fatal and nonfatal cardiovascular event. We used the probability of cardiovascular events as depicted by Friis-Moller et al. 2015 [17]. The probability values in each of three age-related categories were modified by the adequate risk ratio published by Petoumenos 2014 [19]. We have also assumed that the occurrence of a cardiovascular event did not affect the quality of life and generates only additional costs of events and deaths. As part of the searches performed, no data was found about decrease in QOL among

Table 1. Baseline characteristic of patients from TAK cohort.

| Parameters                      | Value |
|---------------------------------|-------|
| Mean CD4+ count [cells/mm³]    | 413.25|
| Median HIV RNA [copies/ml]     | 28 414|
| Mean age [years]               | 36    |
| Females pct. [%]               | 6.00  |
| Black Race pct. [%]            | 0.00  |
| Transmission by IDU [%]        | 1.00  |
| Heterosexual pct. [%]          | 9.93  |
| Homosexual pct. [%]            | 83.69 |
| Bisexual pct. [%]              | 5.67  |

https://doi.org/10.1371/journal.pone.0186131.t001
HIV infected patients after a cardiovascular event. In addition, the structure of the model (cardiovascular events are not separate states of health, but only events) makes it difficult to implement possible values. Also, it should be noted, that the probability of cardiovascular event is the same regardless of the type of cART used. The above simplified assumption is referred to as conservative approach (we charge more costs in the DIG arm than in the IIG). The summary of risk of illnesses used in the model is presented in Tables 3 and 4.

Transmission model

In our model the HIV transmission was assumed to occur only through sexual contacts. The probability of infection through the sex act was conditional on the type of sexual intercourse, as published by Lasry et al. in 2014 [20]. In addition to raw probabilities of transmission per
one sexual act we have included the factor of condom use and cART treatment. We made an assumption, that the only factor determining the rate of HIV transmission between groups is the presence of cART therapy, thus the overall difference in HIV transmission between IIG and DIG persons stems from the difference in transmission rate due to presence or absence of cART and the time lag to cART therapy initiation (in our analysis it was a 1- or 3-year delay).

| Illnesses / event | Mean | Age <50 | Age 50–64 | Age >65 | Source |
|-------------------|------|---------|-----------|--------|--------|
| Hodgkin’s lymphoma | 0.004% | | | | Worm 2013 [16] |
| Non-AIDS defining illnesses | | | | | |
| Liver cancer | 0.003% | | | | Worm 2013 |
| Lung cancer | 0.007% | | | | Worm 2013 |
| Anal cancer | 0.004% | | | | Worm 2013 |
| Pancreatitis | 0.010% | 0.007% | 0.019% | 0.014% | Hasse 2011 [18] |
| End-stage renal disease | 0.001% | | | | Ryom 2014 [14] |
| Liver associated event | 0.021% | 0.019% | 0.030% | 0.007% | Hasse 2011 |
| Cardiovascular events and other diseases | | | | | |
| Fatal myocardial infarction | 0.0036% | 0.0031% | 0.0067% | 0.0090% | Friis-Moller 2015 [17] |
| Fatal stroke | 0.0018% | 0.0015% | 0.0039% | 0.0057% | Friis-Moller 2015 |
| Fatal CHD* | 0.0020% | 0.0017% | 0.0042% | 0.0062% | Friis-Moller 2015 |
| Non-fatal myocardial infarction | 0.0185% | 0.0162% | 0.0345% | 0.0464% | Friis-Moller 2015 |
| Non-fatal stroke | 0.0114% | 0.0098% | 0.0246% | 0.0364% | Friis-Moller 2015 |
| Invasive procedure | 0.0080% | 0.0069% | 0.0168% | 0.0246% | Friis-Moller 2015 |
| Fracture | 0.0137% | 0.0065% | 0.0263% | 0.0426% | Hasse 2011 |
| Diabetes Mellitus | 0.0352% | 0.0352% | 0.0352% | 0.0352% | Petoumenos 2012 [15] |

a) Coronary Heart Disease (CHD)
used in the transmission model were retrieved from Test and Keep in Care project (Table 1) [10]. Three sexual orientations were included in the model (homosexual, heterosexual and bisexual) and we assumed that heterosexual persons had only vaginal intercourse, homosexual have insertive (50%) and receptive (50%) anal sex, and bisexuals had each of them (vaginal, insertive and receptive anal sex in equal part). Additionally, we assumed that each patient from the analysed cohort had the same number of intercourses and had the same number of intercourses with each sexual partner.

We have arbitrarily chosen three profiles of the risk of transmission. For the medium risk scenario, which was considered a baseline model, the rate of transmission was estimated assuming that an average HIV positive person has 10 partners per year, 10 monthly sex acts and 50% frequency of condom use per act. For the low and high risk scenarios used in sensitivity analyses, we assumed a person to have 3 and 50 partners per year, 10 and 20 sex acts per month and 90% and 0% coverage with condom use, respectively. Although the profiles were set arbitrarily, they reflect behavioural patterns observed in the TAK cohort (data according to a standard questionnaire completed by patients prior an HIV test). Over two thirds (75%) of patients reported heterosexual contacts. The average number of casual partners per year was reported by 76% of the patients as fewer than five, six to 20 by 17% and more than 20 by 7%. At the same time, 88% reported not being in stable relationship and only 57% of patients reported using condoms.

Utilities
Baseline utility values used for modelled patients were taken from Golicki et al. reporting utility values of general population in Poland [21]. Utility values were dependent on sex and age. When the person’s health state was changed, the baseline utility was corrected by health state utility multiplier derived from meta-analysis of utility estimates for HIV/AIDS based on time trade off method by Tengs et al. The value of utility of health status used in the Markov was 0.935 for asymptomatic HIV, 0.818 for symptomatic HIV and 0.702 for AIDS [22].

QALY lost and additional costs of new HIV infections
The costs of new HIV infections were added in each cohort to the costs generated in the Markov model. We assumed, that treatment costs of newly infected patients were equal to the total costs estimated in the modelled cohort, discounted to end of the time horizon for the transmission model.

Additionally, we estimated life years gained per HIV-negative patients at the same age as in the input cohort, based on Polish life tables. The obtained estimate was used to calculate life years lost for every newly infected person, as the difference between life years gained (LYG) calculated for an HIV-negative patient and LYG obtained in the Markov model for the corresponding group. All life-years related calculations were discounted.

A similar assumption was adopted to estimate QALY lost. First, we calculated QALY gained per an average HIV-negative person based on Polish lifetable and utility of adult Polish population [21]. Next, we compared the estimated value and the value of QALY calculated with the Markov model, obtaining potential QALY lose by a newly infected person.

Mortality data
General population mortality was estimated on the basis of Polish life tables and baseline characteristics of cohorts (age, gender). Mortality of HIV infected patients without any comorbidities in IIG was retrieved from Stern et al. reporting the probability of death depending on CD4 + count at cART start [23]. We fit a parametric model (exponential distribution) to retrieved
data and compared estimated hazards to data and life tables published by authors (with inclusion of patients with similar characteristics to those included in Stern 2009). The estimated hazard ratio for mortality was used to modify a survival life table used in our model.

For the initial time period of DIG individuals in which they did not receive cART treatment, we used a survival curve estimated in the same way as for IIG individuals, based on data reported by Kovarii et al. [24]. Then, at the start of cART treatment, survival curves for DIG patients were switched to survival curves dependent on published hazard ratios (HR) and are summarized in Table 5.

For the health states defined by AIDS-defining illnesses, basic mortality estimated on the basis of life tables and HR from Stern/Kovarii, was additionally increased by HR values reported by Mocroft et al. [25]. For health states defined by non-AIDS defining illnesses (Hodgkin lymphoma, lung, anal and liver cancer), we used survival curves from Hleyhel 2015, which were extrapolated by fitting exponential distribution [26]. Despite the fact that pancreatitis in patients from general population increases their mortality rate, we did not find any published data regarding mortality of patients with HIV and pancreatitis, so we made the assumption of no increase in mortality rate for these patients. Nevertheless, the probability of pancreatitis is the same regardless of the type of cART used. The above simplified assumption was referred to as conservative approach (we charged more costs in the DIG than in the IIG).

In case of a fatal cardiovascular event, we calculated the probability of death, based on the data reported by Frisch-Moller et al. [17]. Fig 2 presents survival curves used for different lymphocyte CD4+ strata in the base case scenario of our analysis and compares it to lifetable for a 37 years old person from general Polish population.

Costs

In our analysis we did not itemize the costs of specific drugs used in AIDS treatment. Instead, we assumed constant monthly costs of antiretroviral drugs based on the data reported by the National Health Fund (NHF)—the Polish public health care payer. The costs of diseases treatment included in the model were estimated on the basis of published data [27–29]. The costs of treatment of AIDS-defining illnesses were estimated on the basis of the data from the NHF relevant to average costs of hospitalization for specific indications (in Polish payment described by Diagnosis -Related Groups). We made the assumption that the treatment of severe, moderate and mild AIDS defining illnesses required 5, 3 and 1 hospitalization, respectively. The definition of AIDS defining illnesses as severe, moderate or mild was based on the

| Category                                      | Exponential |
|-----------------------------------------------|-------------|
|                                               | HR          | 95% CI      |
| No treatment cART                              | 8.69        | 1.33–16.04  |
| CD4+ cells count at cART initiation            |             |             |
| 451–550                                        | 2.26        | 1.51–3.00   |
| 351–450 (baseline strata for CD4+ count)       | 2.46        | 1.65–3.27   |
| 251–350                                        | 3.32        | 2.22–4.41   |
| 151–250                                        | 4.42        | 2.96–5.87   |
| 51–150                                         | 6.28        | 4.21–8.35   |
| 0–50                                          | 11.93       | 7.99–15.86  |

a) Based on survival curve reported in Kovari 2015
b) Based on survival curves reported in Stern 2009

Table 5. Summary of estimated mortality hazard ratio used in analysis.
study Mocroft 2009 [25]. In case of non-AIDS defining illnesses, treatments for which costs data were not available and for cardiovascular events, the costs were assumed to be equal to the cost of 1 hospitalization. Moreover, for each disease all treatment costs were charged only once (at the disease onset). The summary of cost data is presented in Table 6.

 Costs and effects were discounted at rates of 5% and 3.5%. The cost-effectiveness threshold for incremental cost-effectiveness ratio (ICER) was set to 125 955 Polish new zloty (PLN) (29 312 EUR) according to the Ministry of Health requirements as three times a value of gross domestic product (GDP) per capita [30]

Ethics

The TAK study obtained ethical approval from the Bioethical Committee of the Medical University of Warsaw (AKBE/99/16). All data used in the study were fully anonymized before any of the authors had accessed them.

Results

In the base case analysis, which did not include the effect of HIV transmission, with 20-year time horizon the estimated discounted QALY of a person who started cART therapy immediately at linkage to care (IIG) was 11.29, as compared with 11.15 for a person with cART therapy delayed by 1 year. The calculated total treatment costs were 516,333 PLN for a person
Table 6. Summary of cost categories adopted in the analysis.

| Disease or event                              | Cost of treatment | Source                        |
|-----------------------------------------------|-------------------|-------------------------------|
| Asymptomatic HIV                              |                   |                               |
| ART Treatment                                 | 3 218.07 PLN^a    | KAOS, AOS                     |
| AIDS defining illnesses                       |                   |                               |
| Non-Hodgkin’s lymphoma                        | 122 683.40 PLN    | DRGs^a                        |
| Progressive multifocal leukoencephalopathy    | 32 697.35 PLN     | DRGs                          |
| Cryptococcosis                                | 19 618.41 PLN     | DRGs                          |
| Cerebral toxoplasmosis                        | 19 618.41 PLN     | DRGs                          |
| Invasive cervical carcinoma                   | 19 618.41 PLN     | DRGs                          |
| Bacterial pneumonia                           | 19 618.41 PLN     | DRGs                          |
| AIDS dementia complex                         | 19 618.41 PLN     | DRGs                          |
| Disseminated Mycobacterium avium disease      | 19 618.41 PLN     | DRGs                          |
| Mild                                          | 19 618.41 PLN     | DRGs                          |
| Non-AIDS defining illnesses                  |                   |                               |
| Liver cancer                                  | 88 216.28 PLN     | DRGs                          |
| Lung cancer                                   | 4 005.01 PLN      | NFZ 2011                      |
| Anal cancer                                   | 22 349.23 PLN     | DRGs                          |
| Pancreatitis                                  | 6 573.00 PLN      | DRGs                          |
| End-stage renal disease                       | 66 813.75 PLN     | DRGs                          |
| Liver associated event:                       | 1 953.39 PLN      | DRGs, Kaczor 2012             |
| Hodgkin’s lymphoma                            | 4 679.28 PLN      | DRGs                          |
| Cardiovascular events and other illnesses     |                   |                               |
| Myocardial infarction: nonfatal               | 6 101.18 PLN      | DRGs                          |
| Myocardial infarction: fatal                  | 6 101.18 PLN      | DRGs                          |
| Stroke: no-fatal                              | 7 424.15 PLN      | DRGs                          |
| Stroke: fatal                                 | 7 424.15 PLN      | DRGs                          |
| Invasive procedures (coronary artery coronary by-pass, carotid endarterectomy) | 13 892.14 PLN     | DRGs                          |
| Fracture, inadequate trauma                   | 3 811.16 PLN      | Amarowicz 2015                |
| Diabetes mellitus                             | 3 206.66 PLN^c    | Kinalska 2002                 |

a) Cost per one cycle
b) DRGs—Diagnosis-Related Groups
c) Cost per one year

https://doi.org/10.1371/journal.pone.0186131.t006

Table 7. Results of analysis for base case scenario (Medium Risk scenario).

| Category                                         | Results (1-year delay / 3-years delay) |
|--------------------------------------------------|---------------------------------------|
|                                                  | IIG          | DIG          | Incremental                |
| Sexual HIV transmission                          | 0.03 / 0.08  | 0.61 / 1.80  | -0.59 / -1.73              |
| Total treatment costs                            | 516 333 / 516 333 | 473 560 / 369 129 | 42 773 / 147 204          |
| Cost of treatment new infections                 | 12 646 / 34 208 | 277 067 / 577 394 | -264 421 / -543 186          |
| Total costs (Total treatment costs + Cost of new infections) | 528 979 / 550 541 | 750 627 / 946 523 | -221 648 / -395 982          |
| QALY                                             | 11.29 / 11.29 | 11.15 / 10.35 | 0.14 / 0.94               |
| QALY lost                                        | 0.04 / 0.12   | 1.13 / 4.43   | -1.09 / -4.31              |
| QALY (adj)                                       | 11.25 / 11.17 | 10.02 / 5.91  | 1.23 / 5.25               |
| ICER                                             |             |              | cost-saving / cost-saving |

https://doi.org/10.1371/journal.pone.0186131.t007
starting treatment immediately and 473,560 PLN for a person with one year cART delayed. The difference in QALY was therefore 0.14 and in cost per QALY reached 313,484 PLN.

In scenario with cART therapy delayed by 3 years, estimated discounted QALY was 10.35, the total treatment costs incurred were 369,129 PLN and the difference in cost per QALY gained, comparing to IIG individual, was 156,335 PLN. In this scenario the cost-effectiveness analysis showed no financial benefit from starting cART therapy immediately, comparing to cART therapy delayed by one or three years since the linkage to care.

Next, we carried out the analysis with the risk of sexual HIV transmission (medium risk scenario) included in the model. The estimated sexual HIV transmission rate within one year of a cART therapy delay was 0.61, which is 0.59 more than for persons receiving cART immediately at linkage to care (Table 7). A higher transmission rate in persons without cART leads to additional decrease of QALY of newly infected persons and additional costs of treatment associated with new infections. Estimated additional QALY lost due to HIV transmission was 0.04 per IIG person and 1.13 in DIG and the overall difference in QALY between IIG and DI was 1.23. The additional costs of treatment associated with new infections were 277,067 PLN in DIG, that is 264,421 PLN more than for IIG persons, which leads to the total costs incurred higher by 221,648 PLN. Immediate cART therapy was found to be more cost-saving than therapy delayed by one year since the linkage to care (Table 7).

The estimated total sexual HIV transmission in DIG during initial three years of cART delay was 1.80, which was 1.73 more than in IIG during the same period. Estimated additional QALY lost due to HIV transmission was 0.12 in IIG and 4.43 in DIG, leading to overall difference 5.91 QALY. The additional costs of treatment associated with transmissions were 577,394 PLN in DIG, which was 543,186 PLN more than in IIG, and the total costs incurred in DIG were 395,982 PLN more than in IIG. Thus, in scenario with a three-year delay, immediate cART therapy dominates delayed cART therapy.

Sensitivity analyses
To test, whether the model is robust and the inference is sensitive we have run the model with two additional scenarios of the transmission rate (see Methods). At low transmission risk scenario, estimated one year HIV transmission was 0.01 in IIG and 0.28 in DIG, while during three years estimated transmission was 0.04 in IIG and 0.82 in DIG. At high risk scenario, estimated transmission during one year was 0.09 in IIG and 2.07 in DIG, while during three years estimated transmission was 0.25 in IIG and 6.11 in DIG. In both, a low and high risk scenario immediate cART dominates therapy delayed by one or three years, thus, changing the risk of transmission leads to the same conclusion as in the medium risk scenario. The results of sensitivity analyses are presented in Table 8.

Discussion
Our analyses were performed to compare two hypothetical, independent cohorts of patients, one linked to immediate care and cART treatment, while the second cohort started cART treatment after one- or three-year delay. In base case analysis we did not include the risk of transmission while the person is not on cART, nor the costs related to new infections resulted from delaying treatment. In this case all ICER values comparing immediate cART with one year delayed cART were above the willingness-to-pay threshold. When comparing immediate cART with a three-year cART delay, 19.7% of values were cost-effective and 80.3% were above the willingness-to-pay threshold.

In all scenarios comprising effect of low, medium and high risk of sexual HIV transmission, all values generated with PSA showed the dominance of immediate cART therapy over both
one and three years delayed cART. In all scenarios probabilistic sensitivity analyses were performed around key variables, confirming the robustness of the model (Figs 3 and 4).

This is, to our best knowledge, the first model to investigate the costs-effectiveness of cART in a central European country, which includes a benefit of protecting the HIV transmission. In Table 8. Results of sensitive analysis (Low Risk scenario and High Risk scenario).

| Category                              | Results (1-year delay / 3-years delay) | Incremental       |
|---------------------------------------|---------------------------------------|-------------------|
|                                       | IIG         | DIG       |                  |
| **Low Risk Scenario**                 |            |           |                  |
| Sexual HIV transmission               | 0.01 / 0.04 | 0.28 / 0.82 | -0.27 / -0.78    |
| Total treatment costs                 | 516 333 / 516 333 | 473 560 / 369 129 | 42 773 / 147 204 |
| Cost of treatment new infections      | 5 895 / 15 947 | 125 975 / 262 526 | -120 080 / -246 580 |
| Total costs (Total treatment costs + Cost of new infections) | 522 228 / 532 280 | 599 536 / 631 656 | -77 307 / -99 376 |
| QALY                                  | 11.29 / 11.29 | 11.15 / 10.35 | 0.14 / 0.94      |
| QALY lost                             | 0.02 / 0.06 | 0.52 / 2.02 | -0.50 / -1.96    |
| QALY (adj)                            | 11.27 / 11.23 | 10.64 / 8.33 | 0.63 / 2.90      |
| ICER                                  |            |           |                  |
| **High Risk Scenario**                |            |           |                  |
| Sexual HIV transmission               | 0.09 / 0.25 | 2.07 / 6.11 | -1.99 / -5.86    |
| Total treatment costs                 | 516 333 / 516 333 | 473 560 / 369 129 | 42 773 / 147 204 |
| Cost of treatment new infections      | 42 181 / 114 103 | 939 075 / 1 956 986 | -896 894 / -1 842 882 |
| Total costs (Total treatment costs + Cost of new infections) | 558 515 / 630 437 | 1 412 636 / 2 326 115 | -854 121 / -1 695 678 |
| QALY                                  | 11.29 / 11.29 | 11.15 / 10.35 | 0.14 / 0.94      |
| QALY lost                             | 0.15 / 0.41 | 3.84 / 15.03 | -3.70 / -14.62   |
| QALY (adj)                            | 11.14 / 10.88 | 7.31 / -4.68 | 3.83 / 15.56     |
| ICER                                  |            |           |                  |

a) The difference between 1-year delay / 3-years delay in IIG due to the fact that the period for which we count the number of transmission depends on the delayed therapy.

https://doi.org/10.1371/journal.pone.0186131.t008

 Incremental Cost of Immediate Initiation Group vs Deferred Initiation Group per QALY. Scatter Plot

https://doi.org/10.1371/journal.pone.0186131.g003

one and three years delayed cART. In all scenarios probabilistic sensitivity analyses were performed around key variables, confirming the robustness of the model (Figs 3 and 4).

This is, to our best knowledge, the first model to investigate the costs-effectiveness of cART in a central European country, which includes a benefit of protecting the HIV transmission. In
many Central European countries the epidemic is now driven by sexual contacts, especially among men who have sex with men [31–35]. At the same time these countries often cannot afford to follow the most recent standards of care, namely starting treatment at the time of HIV diagnosis [36, 37]. Our work directly addresses the current needs of governments and stakeholders to base public spending on evidence-based data.

There is a number of limitations which need to be considered while interpreting our data. First of all, comprehensive evaluation of additional costs associated with new infections is relatively hard. A newly infected person can infect others, thus, during his lifetime costs associated with new, consecutive HIV infections can grow exponentially. To overcome this problem, in our analysis we included only those new infections that directly come from the modelled patient during time lag to cART therapy initiation. Moreover, the estimation of the number of newly infected persons was made only for sexual transmission, nevertheless, other ways of HIV transmission exist. It should be also emphasised, that an estimation of the sexual transmission is a very complicated process, encumbered with many uncertainties. Lack of adequate data about the number of regular or casual sexual partners, the number of sexual intercourses and the frequency of condom use can affect the number of HIV transmissions resulting in overestimation of associated costs. However, it is somewhat unrealistic to expect a high precision in information related to sexual behaviours, since persons with many sexual partners and intercourses might have a problem in recalling their sexual practices. This becomes even more difficult when psychoactive substances are used along with sexual behaviours (chemsex) [38]. It is also important to point out that we have estimated number of new HIV infections only for a period of time when patients were not on cART (maximum time 3 years) and assumed no infection occurs immediately after starting cART.

The characteristics of patients are based on relatively a small sample of 141 patients from Test and Keep in Care project. However, this is so far the only cohort providing both pre- and in-care data in Poland with information available on sexual risks and behaviours provided by
persons at the time of HIV anonymous testing and linking this information with their later clinical evaluations in an HIV clinic [9, 10].

Initially the number of AIDS incidents was estimated on the basis of CD4+ T-cell counts, viremia and CD4+/CD8+ ratio, which can lead to additional uncertainty of the estimated value due to scarcity of data regarding viremia and CD4+/CD8+ ratio. Finally, we used only CD4+ T-cell counts for the estimation of the number of AIDS incidents, although such an approach still might be imprecise. Nevertheless, the assumptions made in our model are consistent with those adopted by other authors [39–41]. However, such models should be continuously updated with the most recently published better quality data, particularly on linkage to the CD4+ T-cell counts in the long-term horizon.

We have built a model including numerous epidemiological and clinical factors and based on a real-life cohort of HIV positive persons from Poland. We have shown that taking into account HIV transmission in the cost–effectiveness analyses proved immediate initiation of cART at linkage to care to be a cost-saving decision from the point of view of the Ministry of Health and national health funds in Poland. We believe these analyses are also relevant for other central European countries with comparable epidemiology and costs of HIV care.

Supporting information

S1 File.

(XLS)

Acknowledgments

This study has been supported by Gilead Sciences Poland by covering the cost of work performed by HTA commercial company. However the funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in the ‘author contributions’ section. JR and GW are hired by HTA company. ES is hired by the Gilead Sciences Poland company. JDK is not hired by any of this commercial institutions and did not receive financial support or author’s salary in relation to this work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceptualization: Justyna D. Kowalska, Grzegorz Wójcik, Jakub Rutkowski, Magdalena Ankiersztejn-Bartczak, Ewa Siewaszewicz.

Data curation: Justyna D. Kowalska, Grzegorz Wójcik, Jakub Rutkowski.

Formal analysis: Grzegorz Wójcik, Jakub Rutkowski.

Funding acquisition: Magdalena Ankiersztejn-Bartczak, Ewa Siewaszewicz.

Investigation: Justyna D. Kowalska, Grzegorz Wójcik, Jakub Rutkowski, Magdalena Ankiersztejn-Bartczak.

Methodology: Justyna D. Kowalska, Grzegorz Wójcik, Jakub Rutkowski, Ewa Siewaszewicz.

Supervision: Justyna D. Kowalska, Ewa Siewaszewicz.

Validation: Grzegorz Wójcik, Jakub Rutkowski.

Visualization: Justyna D. Kowalska, Grzegorz Wójcik, Jakub Rutkowski.
Writing – original draft: Justyna D. Kowalska, Grzegorz Wójcik, Jakub Rutkowski, Magdalena Ankiersztejn-Bartczak, Ewa Siewaszewicz.

Writing – review & editing: Justyna D. Kowalska, Grzegorz Wójcik, Jakub Rutkowski.

References

1. Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, et al. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS. 2012; 26(3):315–23. doi: 10.1097/QAD.0b013e32834e8805. PMID: 22112597

2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998; 352(9142):1725–30. PMID: 9848347

3. Kahn JG, Marseille EA, Bennett R, Williams BG, Granich R. Cost-effectiveness of antiretroviral therapy for prevention. Curr HIV Res. 2011; 9(6):405–15. https://doi.org/10.2174/157016211798038542 PMID: 21999776; PubMed Central PMCID: PMCPMC3529401.

4. Global AIDS Update 2016. UNAIDS. Available at: http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016.

5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumaranayake L, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493–505. https://doi.org/10.1056/NEJMoa1105243 PMID: 21767103; PubMed Central PMCID: PMC3200068.

6. Rodger AJ, Cambiano V, Bruun T, Vernaoppa R, Collins S, van Lunzen J, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 2016; 316(2):171–81. https://doi.org/10.1001/jama.2016.5148 PMID: 27404185.

7. Kerr CC, Stuart RM, Gray RT, Shattock AJ, Fraser-Hurt N, Benedikt C, et al. Optima: A Model for HIV Epidemic Analysis, Program Prioritization, and Resource Optimization. J Acquir Immune Defic Syndr. 2015; 69(3):365–76. https://doi.org/10.1097/QAI.0000000000000605 PMID: 25803164.

8. Tan-Torres Edejer T, Baltussen R, Adam T, et al., editors. WHO Guide to Cost-Effectiveness Analysis. WHO, Geneva. 2003. p. 245. Available at: www.who.int/choice/publications/p_2003_generalis_ed_cea.pdf.

9. Ankiersztejn-Bartczak M, Firlag-Burkacka E, Czeszko-Paprocka H, Kubicka J, Cybula A, Horban A, et al. Factors responsible for incomplete linkage to care after HIV diagnosis: preliminary results from the Test and Keep in Care (TAK) project. HIV Med. 2015; 16(2):88–94. https://doi.org/10.1111/hiv.12175 PMID: 25123958.

10. Kowalska JD, Shepherd L, Ankiersztejn-Bartczak M, Cybula A, Czeszko-Paprocka H, Firlag-Burkacka E, et al. Poor Linkage to Care Despite Significant Improvement in Access to Early cART in Central Poland—Data from Test and Keep in Care (TAK) Project. PLoS One. 2016; 11(10):e0162739. https://doi.org/10.1371/journal.pone.0162739 PMID: 27711599; PubMed Central PMCID: PMCPMC5053409.

11. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007; 370(9585):407–13. https://doi.org/10.1016/S0140-6736(07)60948-9 PMID: 17659333.

12. Natural History Project Working Group for the Collaboration of Observational HIVERIE. Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. AIDS. 2014; 28(9):1351–6. https://doi.org/10.1097/QAD.0000000000000224 PMID: 24959963; PubMed Central PMCID: PMC4032217.

13. Mocroft A, Rurrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, et al. The incidence of AIDS-defining illnesses at a current CD4 count >/= 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013; 57(7):1038–47. https://doi.org/10.1093/cid/cit423 PMID: 23921881.

14. Ryom L, Mocroft A, Kirk O, Ross M, Reiss P, Fux CA, et al. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS. 2014; 28(2):187–99. https://doi.org/10.1097/QAD.000000000000042 PMID: 24361680.

15. Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, et al. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc. 2012; 15(2):17426. https://doi.org/10.7448/IAS.15.2.17426 PMID: 23078769; PubMed Central PMCID: PMC3484158.

16. Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fatkenheuer G, et al. Non-AIDS defining cancers in the D:A:D Study—time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013; 13:471.
https://doi.org/10.1186/1471-2334-13-471 PMID: 24106926; PubMed Central PMCID: PMCPMC3852673.

17. Friis-Moller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016; 23(2):214–23. https://doi.org/10.1177/2047871515579291 PMID: 25882821.

18. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011; 53(11):1130–9. https://doi.org/10.1093/cid/cir626 PMID: 21998280.

19. Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, et al. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. HIV Med. 2014; 15(10):595–603. https://doi.org/10.1111/hiv.12162 PMID: 24804675.

20. Lasry A, Sansom SL, Wolitski RJ, Green TA, Borkowf CB, Patel P, et al. HIV sexual transmission risk among serodiscordant couples: assessing the effects of combining prevention strategies. AIDS. 2014; 28(10):1521–9. https://doi.org/10.1097/QAD.0000000000000307 PMID: 24804859.

21. Goëlicki D, Niewada M. General population reference values for 3-level EQ-5D (EQ-5D-3L) questionnaire in Poland. Pol Arch Med Wewn. 2015; 125(1–2):18–26. PMID: 25578383.

22. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002; 22 (6):475–81. https://doi.org/10.1177/0272989X02238300 PMID: 12458977.

23. When To Start C, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009; 373(9672):1352–63. https://doi.org/10.1016/S0140-6736(09)60612-7 PMID: 19361855; PubMed Central PMCID: PMCPMC2670965.

24. Kovari H, Ledergerber B, Cavassini M, Ambrosioni J, Bregenzer A, Stockle M, et al. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. J Hepatol. 2015; 63(3):573–80. 10.1016/j.jhep.2015.04.019. https://doi.org/10.1016/j.jhep.2015.04.019 PMID: 25937433.

25. Antiretroviral Therapy Cohort C, Mocroft A, Sterne JA, Egger M, May M, Grabar S, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis. 2009; 48(8):1138–51. 10.1086/597468. 19275488; PubMed Central PMCID: PMCPMC3032444. https://doi.org/10.1086/597468 PMID: 19275488.

26. Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pecanowski J, Genet P, et al. Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. Int J Cancer. 2015; 137(10):2443–53. https://doi.org/10.1002/ijc.29603 PMID: 25978897.

27. Kinalska I, Niewada M, Głogowski C, Krzycińska J, Latek M, Kamiński B. Koszty czteru typu 2 w Polsce (Badanie CODIP), Diabetologia Praktyczna 2004; 5(1):1–8.

28. Kaczor MP, Pawlik D, Wojcik R, Tronczynski K, Wiśniewski J, Łatek M, Kamiński B. Koszty czteru typu 2 w Polsce (Badanie CODIP), Diabetologia Praktyczna 2004; 5(1):1–8.

29. Kolaric B, Stajduhar D. Risk behaviors for getting HIV infection among the Croatian men who have sex with men in 2007. Coll Antropol. 2011; 35(3):855–9. PMID: 22053567.

30. Rosinska M, Janiec J, Niedzwiedzka-Stadnik M. Increase of new HIV diagnoses among men who have sex with men in Poland, 2000 to 2011. Euro Surveill. 2013; 18(48):20642. PMID: 24308981.

31. Amarowicz J, Boliśega D, Rutkowski J, Kumor A, Czerwiński E. Analiza kosztoeffektywności leczenia złamań osteoporotycznych w powiązaniu z algorytmem FRAX na próbie populacji Polski. Ortopedia Traumatologia Rehabilitacja, MEDSPORTPRESS, 2015; 1(6);59–69.

32. Obwieszczenie Prezesa Głównego Urzędu Statystycznego z dnia 31 października 2016 r. w sprawie szacunków wartości produktu krajowego brutto na jednego mieszkańca w latach 2012–2014 na poziomie województw (NTS2) i podregionów (NTS3) Available at: http://stat.gov.pl/sygnalne/komunikaty-i-obwieszczenia/lista-komunikatow-i-obwieszczenia/obwieszczenie-w-sprawie-szacunkow-wartoosci-produktu-krajowego-brutto-na-jednego-mieszkanca-w-latach-2012-2014-na-pozio-mie-wojewodztw-nts2-i-podregionow-nts3-281-3.html Accessed 02August2017.

33. Státní zdravotní ústav. Czech Republic. Zpráva o výskytu a šíření HIV/AIDS za rok 2015. Available at: http://www.szu.cz/tema/prevence/zprava-o-vyskytu-a-sireni-hiv-aids-za-rok-2015.
36. Kowalska JD, Oprea C, de Witt S, Pozniak A, Gokengin D, Youle M, et al. Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration—a comprehensive meeting report. HIV Med. 2016. https://doi.org/10.1111/hiv.12436 PMID: 27553526.

37. European AIDS Clinical Society Guidelines Version 8.1, October 2016. Available at: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html

38. Schmidt AJ, Bourne A, Weatherburn P, Reid D, Marcus U, Hickson F, et al. Illicit drug use among gay and bisexual men in 44 cities: Findings from the European MSM Internet Survey (EMIS). Int J Drug Policy. 2016; 38:4–12. https://doi.org/10.1016/j.drugpo.2016.09.007 PMID: 27788450.

39. Prabhu VS, Farnham PG, Hutchinson AB, Soorapanth S, Heffelfinger JD, Golden MR, et al. Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis. PLoS One. 2011; 6(5):e19936. https://doi.org/10.1371/journal.pone.0019936 PMID: 21625489; PubMed Central PMCID: PMC3098845.

40. Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV Med. 2016; 17(7):505–15. https://doi.org/10.1111/hiv.12349 PMID: 26663715.

41. Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010; 28 Suppl 1:147–67. https://doi.org/10.2165/11587500-000000000-00000 PMID: 21182349.